Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 20/20 | 0.63 |
| ▸ | KDR | P35968 | 20/20 | 0.63 |
| ▸ | MST1R | Q04912 | 2/20 | 0.54 |
| ▸ | AURKA | O14965 | 1/20 | 0.51 |
| ▸ | FPR1 | P21462 | 1/20 | 0.51 |
| ▸ | FPR3 | P25089 | 1/20 | 0.51 |
| ▸ | GPR183 | P32249 | 1/20 | 0.51 |
| ▸ | SMO | Q99835 | 1/20 | 0.51 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL307604 | 0.93 | MET (0.60) | METKDRMST1R | |
| SCHEMBL307273 | 0.92 | MET (0.60) | METKDRMST1R | |
| SCHEMBL308135 | 0.91 | MET (0.59) | METKDRMST1RAURKAFPR1 | |
| SCHEMBL307087 | 0.91 | MET (0.69) | METKDRMST1R | |
| SCHEMBL895577 | 0.91 | MET (0.61) | METKDRMST1R | |
| SCHEMBL306289 | 0.89 | MET (0.72) | METKDRMST1RAURKAFPR1 | |
| SCHEMBL18487294 | 0.87 | MET (0.66) | METKDRMST1R | |
| SCHEMBL18487293 | 0.86 | MET (0.68) | METKDRMST1R | |
| SCHEMBL306356 | 0.86 | MET (0.79) | METKDRMST1R | |
| SCHEMBL18487296 | 0.85 | MET (0.75) | METKDRMST1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1957498-B1 | INHIBITORS OF VEGF RECEPTOR AND HGF RECEPTOR SIGNALING | METHYLGENE INC (CA) | 2017-02-15 | — | — | EP | claimed |
| US-8329726-B2 | Inhibitors of VEGF receptor and HGF receptor signaling | METHYLGENE INC. (CA) | 2012-12-11 | — | — | US | claimed |
| US-20120083482-A1 | INHIBITORS OF VEGF RECEPTOR AND HGF RECEPTOR SIGNALING | METHYLGENE INC. | 2012-04-05 | — | — | US | claimed |
| EP-1957498-B1 | INHIBITORS OF VEGF RECEPTOR AND HGF RECEPTOR SIGNALING | METHYLGENE INC (CA) | 2017-02-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120083482-A1 | INHIBITORS OF VEGF RECEPTOR AND HGF RECEPTOR SIGNALING | HGF, MET, KDR | MET 2/4885KDR 3/4885MST1R 56/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.